Cargando…
Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial
Myotonic dystrophy type 1 (DM1) is a rare genetic disorder, characterised by muscular dystrophy, myotonia, and other symptoms. DM1 is caused by the expansion of a CTG repeat in the 3’-untranslated region of DMPK. Longer CTG expansions are associated with greater symptom severity and earlier age at o...
Autores principales: | Kurkiewicz, Adam, Cooper, Anneli, McIlwaine, Emily, Cumming, Sarah A., Adam, Berit, Krahe, Ralf, Puymirat, Jack, Schoser, Benedikt, Timchenko, Lubov, Ashizawa, Tetsuo, Thornton, Charles A., Rogers, Simon, McClure, John D., Monckton, Darren G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156058/ https://www.ncbi.nlm.nih.gov/pubmed/32287265 http://dx.doi.org/10.1371/journal.pone.0231000 |
Ejemplares similares
-
Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
por: Schoser, Benedikt, et al.
Publicado: (2010) -
Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
por: Timchenko, Lubov
Publicado: (2022) -
Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
por: Timchenko, Lubov
Publicado: (2022) -
Core Clinical Phenotypes in Myotonic Dystrophies
por: Wenninger, Stephan, et al.
Publicado: (2018) -
GSK3β is a new therapeutic target for myotonic dystrophy type 1
por: Wei, Christina, et al.
Publicado: (2013)